Biotech Values

[Mpower]

From the Q2 Teva Conference Call (July 27th, 2010)

Bill Marth

Good morning, Ken and thanks for the question. With respect to our Lovenox file, we are continuing to dialogue with the agency. I would say to you that we feel that we're on track. We're progressing ahead. We did file slightly later, about a month later than Momenta on the response the immunogenicity, which is very likely why we haven't received our notification yet.

It's almost October ... the 1 month "timing" excuse is over due by a month. Interesting....